Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Re Agreement

13 Aug 2007 07:00

Embargoed Release: 07:00hrs Monday 13 August 2007

SOPHEON PLC ("Sopheon") SOPHEON NAMED TO ENABLE TRANSITION OF IDe CUSTOMERS Arrangement Extends Sopheon's Position as Industry's Leading Provider of Product Roadmapping, Planning and Process Automation Solutions

Sopheon plc announces today that its affiliate, Sopheon Corporation, has entered into an agreement with Integrated Development Enterprise, Inc. ("IDe") under which Sopheon intends to offer transition services and support to IDe customers previously covered by IDe maintenance and support contracts. The agreement follows a recent decision by IDe to discontinue its business.

Founded in 1998, Boston-based IDe specialized in providing product portfolio management software solutions to large manufacturers and services companies. IDe has announced Sopheon, a former competitor, to its customers as an alternate source of services and assistance that IDe will no longer be able to provide.

Terms of the agreement afford Sopheon exclusive access to such IDe assets as its customer list, software code and all documentation relating to IDe's software. Sopheon intends to contact each of IDe's customers to discuss potential support options, including transitioning to Sopheon's Accolade‚® software and services. However, Sopheon is not committed to assume, nor is it legally bound to, any of IDe's obligations to IDe's former end-users, and terms and conditions of the transition will be as agreed between Sopheon and IDe's individual customers. IDe's client base of 18 companies is approximately one-fifth the size of Sopheon's and similarly includes many Fortune 1000 companies.

Sopheon's outreach to IDe customers began last week. Sopheon said that it views the initiative as a unique opportunity to expand its customer population while also increasing maintenance and support revenue.

Less than 60 days ago, Sopheon was successful in a bid to acquire the assets of Alignent Software, a California-based supplier of advanced product and technology roadmapping solutions. The consolidation of Alignent enabled Sopheon to extend its product life cycle management solution footprint to include product planning. Sopheon believes that the agreement with IDe will build on Sopheon's history of steady, substantial growth in the expanding product portfolio and innovation process management market. Since Sopheon's launch of its Accolade solution six years ago, its Accolade-related revenues in dollar terms have increased at an average rate of nearly 50% per year.

Barry Mence, chairman of Sopheon, commented:

"There is good compatibility between IDe's flagship offering and Sopheon's Accolade. There is also a strong fit between our client bases. Add to this the fact that we already know a fair amount about IDe's application, and we believe we are in a position to offer a seamless transition to IDe customers."

For further information contact:

Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO David Newton Seymour Pierce Limited Tel: +44 (0) 207 107 8000 Jonathan Wright, Nominated Advisers Andrew Tan Hansard Group Tel : + 44 (0) 207 245 1100 + 44 (0) 7957 203 685 Floor van Maaren Citigate First Financial Tel : + 31 (0) 205 754 010 About Sopheon

Sopheon is an international provider of software and services that help organizations improve the business impact of product innovation. Sopheon's Accolade system automates and governs the innovation process, enabling companies to increase revenue and profits from new products. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com.

SOPHEON PLC
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.